Pricing Log in Create free account
Friday 6 November 2026 Export BCRX’s income statement to Excel — free account

BioCryst Pharmaceuticals, Inc.

BCRX Healthcare Drug Manufacturers Specialty & Generic

BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.

Revenue
+13.1%
EPS
+150.0%
Free cash flow
−18.7%
Total debt
+15.2%

Quarter to September 2026, against a year earlier

7.53 0.10 −1.31%
Market cap
$2.0B
P/E
0.0×
Fwd P/E
−3.7×
Dividend yield
—
F-score
7/9
Altman Z
1.83
Beneish M
−2.27
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

BioCryst Pharmaceuticals, Inc. (BCRX) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, BioCryst Pharmaceuticals, Inc. (BCRX) trades at a P/S ratio of 2.0×. Over the past ten years it has ranged from 1.5× (February 2026) to 128× (March 2021); the current reading is higher than 1% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 2.1× and below the Healthcare sector median of 3.5×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 1.9× (45.74%)
FY2024 3.4× (2.03%)
FY2023 3.5× (55.21%)
FY2022 7.9× (50.20%)
FY2021 15.8× (77.44%)
FY2020 70.0× 756.66%
FY2019 8.2× (79.74%)
FY2018 40.3× 121.04%
FY2017 18.2× 2.55%
FY2016 17.8× 14.09%

Quarterly newest first

Period P/S ratio Change
Sep 2026 2.2× (18.14%)
Jun 2026 2.7× 3.90%
Mar 2026 2.6× 39.14%
Dec 2025 1.9× (29.63%)
43 more quarters

Against its own ten years

Low 1.5× High 128×
Ten-year median 13.0×
Current reading's percentile 2

P/S ratio against peers

Company P/S ratio
HCM HUTCHMED (China) Limited Sponsored ADR compare n/m
PRGO Perrigo Company plc compare 0.5×
ANIP ANI Pharmaceuticals, Inc. compare 1.4×
PBH Prestige Consumer Healthcare Inc. compare 1.8×
TRLV Trulieve Cannabis Corp. compare 2.0×
BCRX BioCryst Pharmaceuticals, Inc. 2.0×
ALVO Alvotech compare 4.6×
XERS Xeris Biopharma Holdings, Inc. compare 6.4×
RGC Regencell Bioscience Holdings Limited compare —
Drug Manufacturers Specialty & Generic industry median 2.1×
Healthcare sector median 3.5×
Market median 1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on BCRX